Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure
NCT ID: NCT03508271
Last Updated: 2019-01-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60000 participants
OBSERVATIONAL
2017-11-30
2018-11-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
NCT03087487
Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation
NCT02919982
Evaluation of Safety and Effectiveness on Oral Anticoagulants
NCT03765242
Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation
NCT03570047
Adherence to Oral Anticoagulants in Patients With Atrial Fibrillation
NCT05469308
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Elderly individuals with NVAF and HF who are taking OAC's
Non-Interventional
Non-Interventional
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non-Interventional
Non-Interventional
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Had greater than or equal to 1 diagnosis of AF prior to or on the index date
* Had greater than or equal to 1 diagnosis claim of HF during the 12 months prior to or on the index date
* Had 1 or more pharmacy claim for oral blood thinners
Exclusion Criteria
* Pharmacy claim for warfarin, apixaban, dabigatran, edoxaban or rivaroxaban during the 12-month baseline period
* Greater than 1 oral anticoagulants prescription claim on the index date and/or with a follow-up less than 1 day
* Had medical claim indicating VTE in the 12 months prior to index date
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Ann Arbor, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
Investigator Inquiry Form
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CV185-681
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.